NMDA receptor hypofunction model of schizophrenia.

Several decades of research attempting to explain schizophrenia in terms of the dopamine hyperactivity hypothesis have produced disappointing results. A new hypothesis focusing on hypofunction of the NMDA glutamate transmitter system is emerging as a potentially more promising concept. In this article, we present a version of the NMDA receptor hypofunction hypothesis that has evolved from our recent studies pertaining to the neurotoxic and psychotomimetic effects of PCP and related NMDA antagonist drugs. In this article, we examine this hypothesis in terms of its strengths and weaknesses, its therapeutic implications and ways in which it can be further tested.

[1]  G. Ellison,et al.  Competitive and non-competitive NMDA antagonists induce similar limbic degeneration. , 1994, Neuroreport.

[2]  E. Bullmore,et al.  Society for Neuroscience Abstracts , 1997 .

[3]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[4]  D. Cyril D’Souza,et al.  Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans , 1998, Psychopharmacology.

[5]  Angus C Nairn,et al.  The DARPP-32/protein phosphatase-1 cascade: a model for signal integration 1 Published on the World Wide Web on 22 January 1998. 1 , 1998, Brain Research Reviews.

[6]  E. Domino.  PCP (phencyclidine), historical and current perspectives , 1981 .

[7]  D. Reich,et al.  Ketamine: an update on the first twenty-five years of clinical experience , 1989, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[8]  D. Lodge,et al.  Effects of phencyclidine on excitatory amino acid activation of spinal interneurones in the cat. , 1982, European journal of pharmacology.

[9]  M. Giovannini,et al.  Glutamatergic regulation of acetylcholine output in different brain regions: A microdialysis study in the rat , 1994, Neurochemistry International.

[10]  R. Tandon,et al.  Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia. , 1989, Archives of general psychiatry.

[11]  T. Gordh,et al.  The NMDA-receptor antagonist CPP abolishes neurogenic ‘wind-up pain’ after intrathecal administration in humans , 1992, Pain.

[12]  Tamara Hershey,et al.  Ketamine-Induced NMDA Receptor Hypofunction as a Model of Memory Impairment and Psychosis , 1999, Neuropsychopharmacology.

[13]  G. Rosenbaum,et al.  Study of a new schizophrenomimetic drug; sernyl. , 1959, A.M.A. archives of neurology and psychiatry.

[14]  Dundee Jw,et al.  Ketamine-iorazepam. Attenuation of psychic sequelae of ketamine by lorazepam. , 1978 .

[15]  P. White,et al.  Ketamine--its pharmacology and therapeutic uses. , 1982, Anesthesiology.

[16]  F. Mott.  ARCHIVES OF NEUROLOGY AND PSYCHIATRY , 1923 .

[17]  J. Grotta,et al.  Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial. , 1995, Stroke.

[18]  P S Goldman-Rakic,et al.  Widespread origin of the primate mesofrontal dopamine system. , 1998, Cerebral cortex.

[19]  Herbert Weingartner,et al.  NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers , 1996, Neuropsychopharmacology.

[20]  J. Olney,et al.  Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity , 1996, Schizophrenia Research.

[21]  J. Olney,et al.  Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: Potential relevance to schizophrenia? , 1995, Biological Psychiatry.

[22]  O. Bratfos.  [Clinical use of benzodiazepines]. , 1977, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[23]  J. Olney,et al.  Multifocal brain damage induced by phencyclidine is augmented by pilocarpine , 1997, Brain Research.

[24]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[25]  Bita Moghaddam,et al.  Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex , 1997, The Journal of Neuroscience.

[26]  J. Olney,et al.  α2 Adrenergic Agonists Prevent MK-801 Neurotoxicity , 1995, Neuropsychopharmacology.

[27]  T. Hicks,et al.  Excitatory amino acid transmission , 1987 .

[28]  R. Shader,et al.  Clinical Uses of Benzodiazepines , 1993, Journal of clinical psychopharmacology.

[29]  O. Wolkowitz,et al.  Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. , 1991, The American journal of psychiatry.

[30]  P. Herrling,et al.  d-CPPene (SDZ EAA-494)—A Competitive NMDA Antagonist: Pharmacology and Results in Humans , 1997 .

[31]  D. Cyril D’Souza,et al.  Interactive effects of subanesthetic ketamine and haloperidol in healthy humans , 1999, Psychopharmacology.

[32]  O'Callaghan Jp,et al.  Reactive gliosis induced by MK-801 in the rat posterior cingulate/retrosplenial cortex: GFAP evaluation by sandwich ELISA and immunocytochemistry. , 1995 .

[33]  P S Goldman-Rakic,et al.  5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[34]  B. Moghaddam,et al.  Corticolimbic Dopamine Neurotransmission Is Temporally Dissociated from the Cognitive and Locomotor Effects of Phencyclidine , 1998, The Journal of Neuroscience.

[35]  R. Tandon,et al.  Muscarinic cholinergic hyperactivity in schizophrenia relationship to positive and negative symptoms , 1991, Schizophrenia Research.

[36]  K. Lees,et al.  Effects of prolonged infusions of the NMDA antagonist aptiganel hydrochloride (CNS 1102) in normal volunteers. , 1997, Clinical neuropharmacology.

[37]  J. Olney,et al.  Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. , 1999, Science.

[38]  G. Buzsáki,et al.  MK-801-induced neuronal damage in rats , 1997, Brain Research.

[39]  R. Switzer,et al.  Dissimilar patterns of degeneration in brain following four different addictive stimulants , 1993, Neuroreport.

[40]  J. Olney,et al.  Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity , 1993, Biological Psychiatry.

[41]  J. Olney,et al.  NMDA antagonist neurotoxicity: mechanism and prevention. , 1991, Science.

[42]  G. Rosenbaum,et al.  Comparison of sernyl with other drugs: simulation of schizophrenic performance with sernyl, LSD-25, and amobarbital (amytal) sodium; I. Attention, motor function, and proprioception. , 1959, A.M.A. archives of general psychiatry.

[43]  J. Olney,et al.  Excessive cerebrocortical release of acetylcholine induced by NMDA antagonists is reduced by GABAergic and α2-adrenergic agonists , 1999, Molecular Psychiatry.

[44]  R. Buchanan,et al.  Diazepam treatment of early signs of exacerbation in schizophrenia. , 1999, The American journal of psychiatry.

[45]  G. Rosenbaum,et al.  Comparison of phencyclidine hydrochloride (Sernyl) with other drugs. Simulation of schizophrenic performance with phencyclidine hydrochloride (Sernyl), lysergic acid diethylamide (LSD-25), and amobarbital (Amytal) sodium; II. Symbolic and sequential thinking. , 1962, Archives of general psychiatry.

[46]  P. Goldman-Rakic,et al.  Localization of the m2 muscarinic acetylcholine receptor protein and mRNA in cortical neurons of the normal and cholinergically deafferented rhesus monkey , 1998, The Journal of comparative neurology.

[47]  J. Magbagbeola,et al.  Effect of thiopentone on emergence reactions to ketamine anaesthesia , 1974, Canadian Anaesthetists' Society journal.

[48]  J. Olney,et al.  Serotonergic Agents That Activate 5HT2A Receptors Prevent NMDA Antagonist Neurotoxicity , 1998, Neuropsychopharmacology.

[49]  P. Goldman-Rakic,et al.  D1 Receptor in Interneurons of Macaque Prefrontal Cortex: Distribution and Subcellular Localization , 1998, The Journal of Neuroscience.

[50]  J. Olney,et al.  Halothane prevents MK-801 neurotoxicity in the rat cingulate cortex , 1995, Neuroscience Letters.

[51]  J. Olney,et al.  Isoflurane and Propofol Block Neurotoxicity Caused by MK-801 in the Rat Posterior Cingulate/Retrosplenial Cortex , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[52]  H. Kinoshita,et al.  MK-801 increases endogenous acetylcholine release in the rat parietal cortex: a study using brain microdialysis , 1993, Neuroscience Letters.

[53]  C. Ikonomidou,et al.  Hypobaric-ischemic conditions produce glutamate-like cytopathology in infant rat brain , 1989, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[54]  J. Olney,et al.  Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. , 1989, Science.

[55]  J. Yesavage,et al.  Acute phencyclidine (PCP) intoxication: psychopathology and prognosis. , 1978, The Journal of clinical psychiatry.

[56]  R. H. Evans,et al.  Excitatory amino acid transmitters. , 1981, Annual review of pharmacology and toxicology.

[57]  D. Javitt,et al.  Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.

[58]  A. Malhotra,et al.  Clozapine Blunts N-Methyl-d-Aspartate Antagonist-Induced Psychosis: A Study with Ketamine , 1997, Biological Psychiatry.

[59]  A. Streissguth,et al.  Mental illness in adults with fetal alcohol syndrome or fetal alcohol effects. , 1998, The American journal of psychiatry.

[60]  J. Olney,et al.  Disseminated Corticolimbic Neuronal Degeneration Induced in Rat Brain by MK-801: Potential Relevance to Alzheimer's Disease , 1998, Neurobiology of Disease.

[61]  J. Olney,et al.  Glutamate receptor dysfunction and schizophrenia. , 1995, Archives of general psychiatry.